MDL | MFCD04114327 |
---|---|
Molecular Weight | 172.57 |
Molecular Formula | C7H5ClO3 |
SMILES | ClC1=CC(O)=CC(C(O)=O)=C1 |
3-Chloro-5-hydroxybenzoic acid is a potent, orally active and selective lactate receptor GPR81 agonist, with an EC 50 of 16 μM for human GPR81. 3-Chloro-5-hydroxybenzoic acid exhibits favorable in vivo effects on lipolysis in a mouse model of obesity [1] .
3-Chloro-5-hydroxybenzoic acid shows potency against human (EC50=16 μM), monkey (EC 50 =17 μM), dog (EC 50 =67 μM), rat (EC 50 =7 μM), mouse (EC 50 =22 μM), and hamster GPR81 (EC 50 =27 μM) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
3-Chloro-5-hydroxybenzoic acid (30, 100, and 300 mg/kg; PO in overnight fasted C57Bl6/J mice fed high fat chow for 10 weeks) shows significant reductions in free fatty acids at all doses tested, resulting in a minimum efficacious dose of 30 mg/kg
[1]
.
Pharmacokinetic Parameters of 3-Chloro-5-hydroxybenzoic acid in Mice
[1]
.
dose (mg/kg) | t max (h) | AUC inf (h ng/mL) | C max (ng/mL) | C max (μM) | t 1/2 (h) |
30 | 0.5 | 9356 | 11689.50 | 67.2 | 1.47 |
100 | 0.5 | 51312 | 55252.80 | 341.9 | 1.10 |
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | C57Bl6/J mice (DIO mice) [1] |
Dosage: | 30, 100, and 300 mg/kg |
Administration: | PO in overnight fasted C57Bl6/J mice fed high fat chow for 10 weeks |
Result: | Significant reductions in nonesterified free fatty acid cholesterol (NEFAc) at all doses tested. |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : ≥ 100 mg/mL ( 579.47 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 5.7947 mL | 28.9737 mL | 57.9475 mL |
5 mM | 1.1589 mL | 5.7947 mL | 11.5895 mL |
10 mM | 0.5795 mL | 2.8974 mL | 5.7947 mL |